Fintel reports that on May 14, 2025, Morgan Stanley downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme have been highlighted in this Screen of The Week article.

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

The stock has declined 10.3% in the past year. Halozyme Therapeutics, a biopharmaceutical company, carries a Zacks Rank #2 and has a VGM Score of A. HALO has a trailing four-quarter earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In another note of news, a key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's ( NVO) Wegovy (semaglutide) and Eli Lilly's ( LLY) Zepbound ...

Tess Stynes - profile from The Wall Street Journal. News, articles, biography and photos.

XMHQ is a high-conviction mid-cap ETF with strong long-term growth potential. It suits investors seeking quality and growth ...

The new version has been developed using the Enhanze drug delivery technology developed by Halozyme, which increases the permeability of the tissue under the skin, giving space for large molecules ...